Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06679582 · ClinicalTrials.gov registry record · Phase 1
Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML
A Phase 1 study, sponsored by Sutro Biopharma.
- Terminated
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT06679582 is a Phase 1 study that was terminated before completion, run by Sutro Biopharma. The registered enrollment target is 24 participants.
The verdict
NCT06679582, a Phase 1 study, was terminated before completion, sponsored by Sutro Biopharma.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This trial will evaluate whether luveltamab tazevibulin is well tolerated and active against a rare form of AML carrying a particular genetic abnormality called CBFA2T3::GLIS2 that arises in infants and children. To be treated in this trial children must have a leukemia which did not respond or recurred after prior treatment. Luveltamab tazevibulin is an antibody-drug conjugate, which brings tazevibulin, an anticancer drug, to a molecule called FOLR1, present on the surface of CBFA2T3::GLIS2 AML cells.
Interventions
- DRUG Luveltamab tazevibulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-12-04 |
| Est. Completion | 2025-06-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06679582
The ClinicalTrials.gov registry entry for NCT06679582 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sutro Biopharma, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Luveltamab tazevibulin is the first listed.
NCT06679582 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06679582 about?
NCT06679582 is a clinical study titled "Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML". This trial will evaluate whether luveltamab tazevibulin is well tolerated and active against a rare form of AML carrying a particular genetic abnormality called CBFA2T3::GLIS2 that arises in infants and children. To be treated in this trial children must have a leukemia which did not respond or recu...
What is the current status of trial NCT06679582?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2024-12-04. Estimated completion is 2025-06-01.
What interventions are being tested in trial NCT06679582?
The interventions under investigation include: Luveltamab tazevibulin (DRUG).
Who is sponsoring clinical trial NCT06679582?
This trial is sponsored by Sutro Biopharma, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.